ERBB2 and central nervous system cancer: Of note, based upon the PATRICIA clinical data, the NCCN Clinical Practice guidelines in Oncology (NCCN Guidelines®) for the management of CNS cancers were first updated in June 2022 to include pertuzumab and high-dose trastuzumab as a new category 2A regimen for patients with HER2-positive MBC and brain metastases (Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.1.2023.